BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 2233723)

  • 1. An amino-terminal c-myc domain required for neoplastic transformation activates transcription.
    Kato GJ; Barrett J; Villa-Garcia M; Dang CV
    Mol Cell Biol; 1990 Nov; 10(11):5914-20. PubMed ID: 2233723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular leucine zipper interactions suggest c-Myc hetero-oligomerization.
    Dang CV; Barrett J; Villa-Garcia M; Resar LM; Kato GJ; Fearon ER
    Mol Cell Biol; 1991 Feb; 11(2):954-62. PubMed ID: 1990293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells.
    Barrett J; Birrer MJ; Kato GJ; Dosaka-Akita H; Dang CV
    Mol Cell Biol; 1992 Jul; 12(7):3130-7. PubMed ID: 1620120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-myc inhibits neoplastic transformation and transcriptional activation by c-myc.
    Resar LM; Dolde C; Barrett JF; Dang CV
    Mol Cell Biol; 1993 Feb; 13(2):1130-6. PubMed ID: 8423780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Domains of human c-myc protein required for autosuppression and cooperation with ras oncogenes are overlapping.
    Penn LJ; Brooks MW; Laufer EM; Littlewood TD; Morgenstern JP; Evan GI; Lee WM; Land H
    Mol Cell Biol; 1990 Sep; 10(9):4961-6. PubMed ID: 2201910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An essential domain of the c-myc protein interacts with a nuclear factor that is also required for E1A-mediated transformation.
    Brough DE; Hofmann TJ; Ellwood KB; Townley RA; Cole MD
    Mol Cell Biol; 1995 Mar; 15(3):1536-44. PubMed ID: 7862146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A point mutation in the MyoD basic domain imparts c-Myc-like properties.
    Van Antwerp ME; Chen DG; Chang C; Prochownik EV
    Proc Natl Acad Sci U S A; 1992 Oct; 89(19):9010-4. PubMed ID: 1329087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional regulation by Fos and Jun in vitro: interaction among multiple activator and regulatory domains.
    Abate C; Luk D; Curran T
    Mol Cell Biol; 1991 Jul; 11(7):3624-32. PubMed ID: 1904542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic activity of the c-Myc protein requires dimerization with Max.
    Amati B; Brooks MW; Levy N; Littlewood TD; Evan GI; Land H
    Cell; 1993 Jan; 72(2):233-45. PubMed ID: 8425220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of the 'leucine zipper' region in the oligomerization and transforming activity of human c-myc protein.
    Dang CV; McGuire M; Buckmire M; Lee WM
    Nature; 1989 Feb; 337(6208):664-6. PubMed ID: 2645525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opposite regulation of gene transcription and cell proliferation by c-Myc and Max.
    Gu W; Cechova K; Tassi V; Dalla-Favera R
    Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2935-9. PubMed ID: 8385351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.
    Blackwood EM; Eisenman RN
    Science; 1991 Mar; 251(4998):1211-7. PubMed ID: 2006410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The alternatively initiated c-Myc proteins differentially regulate transcription through a noncanonical DNA-binding site.
    Hann SR; Dixit M; Sears RC; Sealy L
    Genes Dev; 1994 Oct; 8(20):2441-52. PubMed ID: 7958908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do products of the myc proto-oncogene play a role in transcriptional regulation of the prothymosin alpha gene?
    Mol PC; Wang RH; Batey DW; Lee LA; Dang CV; Berger SL
    Mol Cell Biol; 1995 Dec; 15(12):6999-7009. PubMed ID: 8524267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.
    Kumaraswamy A; Mamidi A; Desai P; Sivagnanam A; Perumalsamy LR; Ramakrishnan C; Gromiha M; Rajalingam K; Mahalingam S
    J Biol Chem; 2018 Oct; 293(40):15691-15705. PubMed ID: 30139745
    [No Abstract]   [Full Text] [Related]  

  • 16. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.
    Rao G; Alland L; Guida P; Schreiber-Agus N; Chen K; Chin L; Rochelle JM; Seldin MF; Skoultchi AI; DePinho RA
    Oncogene; 1996 Mar; 12(5):1165-72. PubMed ID: 8649810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional analysis of the N-terminal domain of the Myc oncoprotein.
    Oster SK; Mao DY; Kennedy J; Penn LZ
    Oncogene; 2003 Apr; 22(13):1998-2010. PubMed ID: 12673205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of gene transcription by the amino terminus of the N-Myc protein does not require association with the protein encoded by the retinoblastoma suppressor gene RB1.
    Cziepluch C; Wenzel A; Schürmann J; Schwab M
    Oncogene; 1993 Oct; 8(10):2833-8. PubMed ID: 8378092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential.
    Katzav S; Cleveland JL; Heslop HE; Pulido D
    Mol Cell Biol; 1991 Apr; 11(4):1912-20. PubMed ID: 2005887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional analysis of the carboxy-terminal transforming region of v-Myc: binding to Max is necessary, but not sufficient, for cellular transformation.
    Min S; Mascarenhas NT; Taparowsky EJ
    Oncogene; 1993 Oct; 8(10):2691-701. PubMed ID: 8378081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.